Skip to Content
HCA HealthONEReturn to HCA HealthONE
HCA HealthONE Swedish
501 E Hampden Ave, Englewood, CO 80113(303) 788 - 5000

Retatrutide is a new GLP-1 hit. But is it legal?

You've heard of the popular (GLP-1) receptor agonist drug semaglutide (Ozempic, Wegovy) and GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound), but there's a new kid on the block.

November 14, 2025
A woman stands on a scale to be weighed, in front of a hospital window.

A phase 3 clinical trial for retatrutide is currently underway and expected to wrap up in May 2026. After the trial is complete, the FDA usually takes 6 to 10 months to review the study once the results are submitted, says Michael Snyder, MD, the medical director of bariatric surgery at HCA HealthONE Rose in Denver, and an in-house obesity specialist at FuturHealth.

Read the MSN article.

Learn more about Dr. Snyder and the team at Denver Center for Bariatric Surgery.

Published:
November 14, 2025
Location:
HCA HealthONE Rose

Related Newsroom Articles

What is influencing a change in obesity rates in the United States
March 05, 2026
New CDC data shows obesity rates for adults maybe slowing, while childhood and teen rates hit record highs.
What is influencing a change in obesity rates in the United States
March 05, 2026
New CDC data shows obesity rates for adults maybe slowing, while childhood and teen rates hit record highs.
For weight loss, this intermittent fasting strategy beat out daily calorie counting
April 10, 2025
A new study found that a 4:3 intermittent fasting plan — with three days of fasting per week — helped people lose more weight than daily calorie counting.